selegiline has been researched along with ubiquinone in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Burger, R; Dirr, A; Götz, ME; Rausch, WD; Riederer, P | 1 |
| Oliveira, CR; Pereira, CM | 1 |
| Dirr, A; Gerlach, M; Gerstner, A; Götz, ME; Harth, R; Janetzky, B; Kuhn, W; Riederer, P | 1 |
| Delanty, N; Praticò, D | 1 |
| Carlson, EC; Ebadi, M; Shavali, S; Swinscoe, JC | 1 |
| LeWitt, PA | 1 |
| Klivényi, P; Rákóczi, K; Vécsei, L | 1 |
| Williams, R | 1 |
3 review(s) available for selegiline and ubiquinone
| Article | Year |
|---|---|
Oxidative injury in diseases of the central nervous system: focus on Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Animals, Genetically Modified; Antioxidants; Ascorbic Acid; Benzoquinones; Central Nervous System; Central Nervous System Diseases; Clinical Trials as Topic; Drug Therapy, Combination; Free Radicals; Ginkgo biloba; Humans; Lipid Peroxidation; Neuroprotective Agents; Oxidation-Reduction; Phytotherapy; Plants, Medicinal; Selegiline; Ubiquinone; Vitamin E | 2000 |
Clinical trials of neuroprotection for Parkinson's disease.
Topics: Antiparkinson Agents; Clinical Trials as Topic; Creatine; Dopamine Agonists; Double-Blind Method; Humans; Indans; Minocycline; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Multicenter Studies as Topic; Nerve Tissue Proteins; Neuroprotective Agents; Oxepins; Parkinson Disease; Picolinic Acids; Randomized Controlled Trials as Topic; Riluzole; Selegiline; Ubiquinone | 2004 |
[Neuroprotection in Parkinson's disease and other neurodegenerative disorders: preclinical and clinical findings].
Topics: Animals; Creatine; Dopamine Agonists; Glatiramer Acetate; Humans; Indans; Kynurenic Acid; Micronutrients; Nerve Degeneration; Neurodegenerative Diseases; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Peptides; Selegiline; Tocopherols; Ubiquinone | 2009 |
5 other study(ies) available for selegiline and ubiquinone
| Article | Year |
|---|---|
High dose selegiline augments striatal ubiquinol in mouse: an indication of decreased oxidative stress or of interference with mitochondrial respiration? A pilot study.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dose-Response Relationship, Drug; Homovanillic Acid; Male; Mice; Mice, Inbred C57BL; Mitochondria; Monoamine Oxidase Inhibitors; Oxidative Stress; Oxygen Consumption; Pilot Projects; Selegiline; Ubiquinone | 1995 |
Glutamate toxicity on a PC12 cell line involves glutathione (GSH) depletion and oxidative stress.
Topics: Animals; Antioxidants; Benzoquinones; Cell Death; Cystine; Dithiothreitol; Glutamic Acid; Glutathione; Glutathione Reductase; Kinetics; L-Lactate Dehydrogenase; Oxidative Stress; PC12 Cells; Rats; Selegiline; Ubiquinone; Vitamin E | 1997 |
Altered redox state of platelet coenzyme Q10 in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antioxidants; Antiparkinson Agents; Biomarkers; Blood Platelets; Coenzymes; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase; Oxidation-Reduction; Parkinson Disease; Selegiline; Ubiquinone | 2000 |
1-Benzyl-1,2,3,4-tetrahydroisoquinoline, a Parkinsonism-inducing endogenous toxin, increases alpha-synuclein expression and causes nuclear damage in human dopaminergic cells.
Topics: Adenosine Triphosphate; alpha-Synuclein; Antioxidants; Blotting, Western; Cell Line, Tumor; Cell Nucleus; Coenzymes; Cysteine Proteinase Inhibitors; Dopamine; Dose-Response Relationship, Drug; Drug Interactions; Gene Expression Regulation; Glutathione; Humans; Immunohistochemistry; Microscopy, Electron; Nerve Tissue Proteins; Neuroblastoma; Neuroprotective Agents; Oligopeptides; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Selegiline; Synucleins; Tetrahydroisoquinolines; Time Factors; Ubiquinone | 2004 |
Slowing the decline.
Topics: Antiparkinson Agents; Clinical Trials as Topic; Creatine; Humans; Indans; Parkinson Disease; Selegiline; Ubiquinone | 2010 |